The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

Grazia Saturno, Filipa Lopes, I Niculescu-Duvaz, Dan Niculescu-Duvaz, A. Zambon, L. Davies, L. Johnson, N. Preece, Rebecca Lee, Amaya Viros Usandizaga, Denys Holovanchuk, M. Pedersen, Robert Mcleary, Paul Lorigan, Nathalie Dhomen, C. Fisher, U Banerji, E. Dean, Matthew Krebs, Martin GoreJ. Larkin, Richard Marais, C Springer

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science